A medical conundrum: Onset of psoriasis in patients receiving anti-tumour necrosis factor agents

Annals of the Rheumatic Diseases

Volumn 65, Issue 12, 2006, Pages 1541-1544

  Ritchlin, C ^a   Tausk, F ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; AZATHIOPRINE; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

ANKYLOSING SPONDYLITIS; BEHCET DISEASE; CLINICAL TRIAL; CROHN DISEASE; DRUG SAFETY; EDITORIAL; ENTERITIS; HUMAN; INFLAMMATION; MEDICAL PRACTICE; META ANALYSIS; NUMMULAR DERMATITIS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; RASH; RHEUMATOID ARTHRITIS; SKIN DEFECT; SKIN INFECTION; SKIN TUMOR; SYSTEMATIC REVIEW; VASCULITIS;

ANTIRHEUMATIC AGENTS; DRUG ERUPTIONS; HUMANS; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33751290054     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.059261     Document Type: Editorial

References (38)

1. Efthimiou P, Markenson JA. Role of biological agents in immune-mediated inflammatory diseases. South Med J 2005;98:192-204.
2. Ritchlin C. Newer therapeutic approaches: spondyloarthritis and uveitis. Rheum Dis Clin North Am 2006;32:75-90.
3. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. J Am Med Assoc 2006;295:2275-85.
4. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005;7:666-76.
5. Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 2006;54(Suppl 2):S67-80.
6. Kary S, Worm M, Audring H, Huscher D, Renelt M, Sorensen H, et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis 2006;65:405-7.
7. Thurber M, Feasel A, Stroehlein J, Hymes SR. Pustular psoriasis induced by infliximab. J Drugs Dermatol 2004;3:439-40.
8. Verea MM, Del Pozo J, Yebra-Pimentel MT, Porta A, Fonseca E. Psoriasiform eruption induced by infliximab. Ann Pharmacother 2004;38:54-7.
9. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005;52:2513-18.
10. Baeten D, Kruithof E, Van den Bosch F, Van den Bossche N, Herssens A, Mielants H, et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003;62:829-34.
11. Haibel H, Spiller I, Strasser C, Rudwaleit M, Dörner T, Sieper J. Unexpected new onset of psoriasis in treatment of ankylosing spondylitis with TNF alpha blocking agents [abstract]. Ann Rheum Dis 2004;63(Suppl 1):405.
12. Michaelsson G, Kajermo U, Michaelsson A, Hagforsen E. Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumor necrosis factor-α in the normal palmar eccrine sweat duct? Br J Dermatol 2005;153:1220-7.
13. Skov L, Baadsgaard O. Bacterial superantigens and inflammatory skin diseases. Clin Exp Dermatol 2000;25:57-61.
14. Tomi N, Kranke B, Aberer E. Staphylococcal toxins in patients with psoriasis, atopic dermatitis, and erythroderma, and in healthy control subjects. J Am Acad Dermatol 2005;53:67-72.
15. Yarwood J, Leung D, Schlievert P. Evidence for the involvement of bacterial superantigens in psoriasis, atopic dermatitis, and Kawasaki syndrome. FEMS Microbiol Lett 2000;192:1-7.
16. Carter JD. Tumour nearosis factor inhibition causing psoriasis? A more plausible explanation exists. Ann Rheum Dis 2006;65:1680.
17. Jacobi A, Antoni C, Manger B, Schuler G, Hertl M. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2005;52(Pt 1):522-6.
18. Spencer JM, Silvers DN, Grossman ME. Pustular eruption after drug exposure: is it pustular psoriasis or a pustular drug eruption? Br J Dermatol 1994;130:514-19.
19. Deng A, Harvey V, Sina B, Strobel D, Badros A, Junkins-Hopkins JM, et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Dermatol 2006;142:198-202.
20. Asumalahti K, Ameen M, Suomela S, Hagforsen E, Michaelsson G, Evans J, et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol 2003;120:627-32.
21. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000;356:1667-71.
22. Banchereau J, Pascual V, Palucka AK. Autoimmunity through cytokine-induced dendritic cell activation. Immunity 2004;20:539-50.
23. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711-23.
24. Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005;202:135-43.
25. Nestle FO, Gilliet M. Defining upstream elements of psoriasis pathogenesis: an emerging role for interferon alpha. J Invest Dermatol 2005;125:xiv-xv.
26. Zenz R, Eferl R, Kenner L, Florin L, Hummerich L, Mehic D, et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005;437:369-75.
27. Sano S, Chan KS, Carbajal S, Clifford J, Peavey M, Kiguchi K, et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 2005;11:43-9.
28. Cook PW, Piepkorn M, Clegg CH, Plowman GD, DeMay JM, Brown JR, et al. Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype. J Clin Invest 1997;100:2286-94.
29. Ladoyanni E, Nambi R. Psoriasis exacerbated by interferon-alpha in a patient with chronic myeloid leukemia. J Drugs Dermatol 2005;4:221-2.
30. Ketikoglou I, Karatapanis S, Elefsiniotis I, Kafiri G, Moulakakis A. Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B. Eur J Dermatol 2005;15:107-9.
31. Seckin D, Durusoy C, Sahin S. Concomitant vitiligo and psoriasis in a patient treated with interferon alfa-2a for chronic hepatitis B infection. Pediatr Dermatol 2004;21:577-9.
32. Downs AM, Dunnill MG. Exacerbation of psoriasis by interferon-alpha therapy for hepatitis C. Clin Exp Dermatol 2000;25:351-2.
33. Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005;64(Suppl 2):ii30-6.
34. Jiang H, Chess L. Regulation of immune responses by T cells. N Engl J Med 2006;354:1166-76.
35. Shevach EM. Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med 2001;193:F41-6.
36. Esparza EM, Arch RH. Glucocorticoid-induced TNF receptor functions as a costimulatory receptor that promotes survival in early phases of T cell activation. J Immunol 2005;174:7869-74.
37. Wang J, Devgan V, Corrado M, Prabhu NS, El-Deiry WS, Riccardi C, et al. Glucocorticoid-induced tumor necrosis factor receptor is a p21 Cip1/WAF1 transcriptional target conferring resistance of keratinocytes to UV light-induced apoptosis. J Biol Chem 2005;280:37725-31.
38. Hanabuchi S, Watanabe N, Wang YH, Wang YH, Ito T, Shaw J, et al. Human plasmacytoid predendritic cells activate NK cells through glucocorticoid-induced tumor necrosis factor receptor-ligand (GITRL). Blood 2006;107:3617-23.